ARTICLE | Company News
Life Technologies, Novartis deal
August 12, 2013 7:00 AM UTC
Life Technologies granted Novartis exclusive rights to use Dynabeads CD3/CD28 Cell Therapy Systems (CTS) for immunotherapies involving T cells modified to express chimeric antigen receptors to treat c...